AlzeCure's NeuroRestore ACD856 Shows Anti-Inflammatory Effects, Leading to New Alzheimer's Patent

AlzeCure Pharma, a pharmaceutical company based in Stockholm, Sweden, has revealed new preclinical data indicating that its NeuroRestore drug candidate, ACD856, exhibits significant anti-inflammatory properties. This development is particularly relevant for treating Alzheimer's disease, as well as other neurodegenerative conditions characterized by brain inflammation. The company has also submitted a new patent application for ACD856, which is being prepared for phase II clinical trials.

The mechanisms of Alzheimer's disease and similar neurodegenerative diseases often involve prolonged inflammation in the brain. This inflammation can lead to the release of toxic substances that damage nerve cells and cause cell death. Pontus Forsell, Head of Discovery and Research at AlzeCure, emphasized the importance of targeting these inflammatory processes, which could potentially open new avenues for ACD856's application.

The new preclinical data suggest that ACD856 has anti-inflammatory effects both in the brain and throughout the body. These effects include relief from clinical inflammatory symptoms and a reduction in several inflammatory markers. This suggests that ACD856 could potentially modify the disease by addressing neuroinflammation, a core feature of conditions like Alzheimer's disease.

Additionally, ACD856 and other substances in AlzeCure's NeuroRestore platform stimulate crucial signaling systems in the brain, such as Brain Derived Neurotrophic Factor (BDNF) and Nerve Growth Factor (NGF). These factors are vital for cognitive functions, including learning and memory. Previous studies have demonstrated that AlzeCure's drug candidates enhance communication between nerve cells, thereby improving cognitive abilities. The new preclinical results further indicate potential neuroprotective and disease-modifying effects.

Martin Jönsson, CEO of AlzeCure, noted that the company continues to strengthen its patent portfolio for the NeuroRestore program. AlzeCure already holds approved patents in major markets such as the USA, Europe, Japan, and China. The recent preclinical findings for ACD856 provide additional evidence of its potential disease-modifying effects against Alzheimer's and other neurodegenerative diseases characterized by neuroinflammation. This bolsters the commercial prospects for this promising substance.

AlzeCure Pharma is dedicated to developing innovative drug therapies for severe diseases affecting the central nervous system, such as Alzheimer's disease and pain. The company is listed on the Nasdaq First North Premier Growth Market and is working on several parallel drug candidates across three research platforms: NeuroRestore, Alzstatin, and Painless.

The NeuroRestore platform includes two symptomatic drug candidates with mechanisms of action that allow for multiple indications, including Alzheimer's disease, cognitive disorders associated with traumatic brain injury, sleep apnea, Parkinson's disease, and depression. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early Alzheimer's treatment. Lastly, the Painless platform targets pain management, featuring candidates like ACD440 for neuropathic pain and TrkA-NAM for severe pain conditions such as osteoarthritis.

AlzeCure's recent preclinical findings underscore the potential of its NeuroRestore platform, particularly ACD856, in addressing diseases with neuroinflammatory components. As the company prepares for phase II clinical studies, these developments highlight the significant advancements being made in the quest for effective treatments for Alzheimer's disease and other neurodegenerative conditions.